The Fibroid Education Center has attracted an unprecedented number of women to focused ultrasound as a solution for their suffering from uterine fibroids. This initiative was created to provide information about the spectrum of options, including “Curawave” as a focused ultrasound treatment that improves quality of life and maintains the option for future fertility.
Read how radiologist Suzanne LeBlang, MD, and the Education Center team have empowered women to make better choices, dramatically increasing the number of FUS procedures performed in Boca Raton, Florida. This successful pilot may lead to other sites collaborating with the Education Center. READ MORE >
On January 17, Jill O’Donnell-Tormey, PhD, CEO and Director of Scientific Affairs of the Cancer Research Institute (CRI), gave a webinar on cancer immunotherapy and CRI’s role in elevating this promising treatment modality into a significant field of medical research. More than 125 people logged in to watch the presentation and ask questions. READ MORE > WATCH NOW >
Peter suffered from tremors since his teenage years and over time the uncontrollable shaking worsened, making everyday tasks challenging. In 2012, he created HopeNet, an ET advocacy group designed to spread awareness and create a community of patients. Last year, Peter sought focused ultrasound treatment and is now getting back to the activities he once enjoyed.
Jessica Lukens has joined the team to steward relationships with existing donors and introduce new supporters to the Foundation’s mission. “It’s exciting to get involved at this transformative time for focused ultrasound,” she says. “I look forward to helping build awareness and momentum in support of this innovative, impactful technology that has the ability to improve millions of patients’ lives.”
A 40-year old mother of two with symptomatic uterine fibroids was treated in August by Dr. Suzanne LeBlang at her clinic in Boca Raton, Florida. The Focused Ultrasound Foundation interviewed her to learn more about her experience with fibroids and how the treatment dramatically improved her symptoms and her life.
Suzanne LeBlang, MD, or “Dr. Susie,” has been an important member of the focused ultrasound community having published papers, delivered numerous scientific talks, and trained many practitioners. She is the Medical Director of the Fibroid Education Center and also serves as the Foundation's Co-Chief Medical Officer. Hear what Dr. LeBlang has to say about her research and her passion for helping women with fibroids.
As focused ultrasound becomes more widespread, many more patients’ lives are being transformed – especially those with movement disorders like essential tremor and Parkinson’s. Watch three patients share their stories with the news media about how the treatment changed their lives.
In an effort to decrease treatment times for focused ultrasound ablation of uterine fibroids, researchers at UCSF designed a clinical trial to target and destroy the fibroid’s blood supply rather than the fibroid tissue itself. Was this method successful?
This month, exciting research was published involving focused ultrasound to open the blood-brain barrier to deliver drugs to metastatic brain tumors, treat a rare type of spinal bone cancer, and reduce eye pressure in glaucoma patients.
Because transcranial focused ultrasound can deliver hyperthermia in a large tissue volume, researchers in Italy wondered if survival could be improved in glioblastoma multiforme (GBM) patients by combining FUS with radiotherapy. They developed a mathematical model of GBM proliferation, formulated equations describing the impact of radiotherapy and heat on GBM, and then predicted the effectiveness of the combination treatment. Could their encouraging findings be validated?
Two Focused Ultrasound Companies Tapped for Technology Innovation Award
France-based Eye Tech Care and Taiwan-based EpiSonica have both received Frost & Sullivan Awards. Eye Tech Care was given the Europe Award for Technology Innovation for their EyeOP1 computer-assisted glaucoma therapy system. EpiSonica garnered the Asia Pacific prize for New Product Innovation for their ArcBLATE uterine fibroid system. Frost & Sullivan recognizes companies that develop technologies that significantly impact functionality and customer value.
SonaCare Medical recently received regulatory clearance to market a new version of Sonablate in the US. It was the first focused ultrasound device to receive FDA approval for ablating prostate tissue. The improved version includes a tool that monitors for changes in tissue composition following energy delivery, altered delivery sequences that reduce overall procedure time by as much as 40 percent, and a modernized look.